solifenacin succinate + mirabegron + tamsulosin hydrochloride

A fixed-dose combination of **solifenacin succinate**, **mirabegron**, and **tamsulosin hydrochloride** formulated for oral administration. This combination targets multiple pathways involved in the pathophysiology of lower urinary tract symptoms, including **overactive bladder (OAB)** and **benign prostatic hyperplasia (BPH)**, particularly in men with persistent symptoms despite monotherapy. - **Solifenacin succinate** is a selective muscarinic acetylcholine receptor antagonist (antimuscarinic), reducing involuntary bladder contractions and urgency. - **Mirabegron** is a β3-adrenergic receptor agonist that relaxes the detrusor smooth muscle during the storage phase, increasing bladder capacity. - **Tamsulosin hydrochloride** is an α1-adrenergic receptor antagonist, reducing urinary outflow resistance and improving voiding symptoms. The combination aims to maximize symptom control via complementary mechanisms, offering a therapeutic strategy for patients inadequately managed with single agents[1][2][3][4][5][6][7]. Safety data indicate increased anticholinergic side effects, particularly from solifenacin, but overall a tolerable profile.